Literature DB >> 4987716

Evaluation of group C meningococcal polysaccharide vaccine in marine recruits, San Diego, California.

L F Devine, W E Pierce, T M Floyd, S L Rhode, E A Edwards, E E Siess, R O Peckinpaugh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4987716     DOI： 10.1093/oxfordjournals.aje.a121176

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN： 0002-9262            Impact factor:   4.897


× No keyword cloud information.
  8 in total

Review 1.  Vaccine trials.

Authors:  C P Farrington; E Miller
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

2.  Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada.

Authors:  P De Wals; M Dionne; M Douville-Fradet; N Boulianne; J Drapeau; G De Serres
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

3.  Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?

Authors:  Theodore F Tsai; Ray Borrow; Hanspeter E Gnehm; Bernard Vaudaux; Ulrich Heininger; Daniel Desgrandchamps; Christoph Aebi; Paul Balmer; Ronald D Pedersen; Bernard Fritzell; Claire-Anne Siegrist
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study.

Authors:  K R Neal; J S Nguyen-Van-Tam; N Jeffrey; R C Slack; R J Madeley; K Ait-Tahar; K Job; M C Wale; D A Ala'Aldeen
Journal:  BMJ       Date:  2000-03-25

5.  Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.

Authors:  P Richmond; R Borrow; J Findlow; S Martin; C Thornton; K Cartwright; E Miller
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

7.  Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

Authors:  R Gold; M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

8.  Characterization of spheroplast membranes of Neisseria meningitidis group B.

Authors:  J C Hill; N R Peterson; E Weiss
Journal:  Infect Immun       Date:  1972-04       Impact factor: 3.441
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.